Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial

Journal of Clinical Oncology

Volumn 34, Issue 20, 2016, Pages 2333-2340

  Cortes, Jorge E ^a   Saglio, Giuseppe ^d   Kantarjian, Hagop M ^a   Baccarani, Michele ^e   Mayer, Jiří ^f   Boqué, Concepción ^g   Shah, Neil P ^b   Chuah, Charles ^h   Casanova, Luis ⁱ   Bradley Garelik, Brigid ^c   Manos, George ^c   Hochhaus, Andreas ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^g HOSPITAL DURAN I REYNALS   (Spain)

^h DUKE NUS MEDICAL SCHOOL   (Singapore)

ⁱ INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^j JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN;

ABDOMINAL PAIN; AGED; ANEMIA; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION;

ADULT; AGED; DASATINIB; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; MUTATION;

EID: 84977485123     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.8899     Document Type: Article

References (46)

1. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010
2. Bristol-Myers Squibb: Sprycel (dasatinib) [prescribing information]. Princeton, NJ, Bristol-Myers Squibb Company, 2015
3. Cortes JE, Hochhaus A, Kim DW, et al: Fouryear (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: Efficacy based on early response. Blood 122:653, 2013 (abstr)
4. Hochhaus A, Kantarjian H: The development of dasatinib as a treatment for chronic myeloid leukemia (CML): From initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol 139:1971-1984, 2013
5. Jabbour E, Kantarjian HM, Saglio G, et al: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494-500, 2014
6. Kantarjian HM, Shah NP, Cortes JE, et al: Dasatinib or imatinib in newly diagnosed chronicphase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123-1129, 2012
7. Alvarado Y, Kantarjian H, O'Brien S, et al: Significance of suboptimal response to imatinib, as defined by the European Leukemia Net, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115:3709-3718, 2009
8. Branford S, Kim DW, Soverini S, et al: Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 30:4323-4329, 2012
9. Hanfstein B, Müller MC, Hehlmann R, et al: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096-2102, 2012
10. Hughes TP, Hochhaus A, Branford S, et al: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758-3765, 2010
11. Hughes TP, Kaeda J, Branford S, et al: Frequency ofmajormolecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
12. Jabbour E, Kantarjian HM, O'Brien S, et al: Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: What is the optimal response? J Clin Oncol 29:4260-4265, 2011
13. Marin D, Hedgley C, Clark RE, et al: Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120:291-294, 2012
14. Marin D, Ibrahim AR, Lucas C, et al: Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232-238, 2012
15. Marin D, Milojkovic D, Olavarria E, et al: European Leukemia Net criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437-4444, 2008
16. Neelakantan P, Gerrard G, Lucas C, et al: Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: Implications for early intervention strategies. Blood 121:2739-2742, 2013
17. Quintás-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315-6321, 2009
18. Wang L, Pearson K, Ferguson JE, et al: The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120:990-999, 2003
19. Hasford J, Pfirrmann M, Hehlmann R, et al: A new prognostic score for survival of patients with chronicmyeloid leukemia treatedwith interferon alfa. J Natl Cancer Inst 90:850-858, 1998
20. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 108:1809-1820, 2006
21. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Reviewand recommendations for harmonizing current methodology for detecting BCRABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006
22. Ludwig H, Bolejack V, Crowley J, et al: Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 28: 1599-1605, 2010
23. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0, August 2006. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
24. Simonneau G, Gatzoulis MA, Adatia I, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62:D34-D41, 2013 (suppl)
25. Valent P, Hadzijusufovic E, Schernthaner GH, et al: Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125: 901-906, 2015
26. Hjorth-Hansen H, Stenke L, Söderlund S, et al: Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (Nord CML006). Eur J Haematol 94: 243-250, 2015
27. O'Brien SG, Hedgley C, Adams S, et al: Spirit 2: An NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML. Blood 124:517, 2014 (abstr)
28. Radich JP, Kopecky KJ, Appelbaum FR, et al: A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120:3898-3905, 2012
29. Sasaki K, Strom SS, O'Brien S, et al: Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: Analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186-e193, 2015
30. Paquette R, Mauro M, Simonsson B, et al: Cardiovascular (CV)-related hospitalization in patients with chronic-phase chronic myeloid leukemia (CPCML) in SIMPLICITY, a prospective observational study. Haematologica 100:E1099, 2015 (abstr)
31. Pemmaraju N, Kantarjian HM, O'Brien S, et al: Phase II clinical trial results of dasatinib for frontline therapy in patients with chronic myeloid leukemia (CML) in chronic phase (CP). Blood 124:4565, 2014 (abstr)
32. Hughes TP, Saglio G, Quintás-Cardama A, et al: BCR-ABL1 mutation development during firstline treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia 29: 1832-1838, 2015
33. Jabbour E, Kantarjian H, Jones D, et al: Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20: 1767-1773, 2006
34. Cohen MH, Williams G, Johnson JR, et al: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942, 2002
35. Yilmaz M, Lahoti A, O'Brien S, et al: Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121:3894-3904, 2015
36. Shah NP, Wallis N, Farber HW, et al: Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90:1060-1064, 2015
37. Novartis: Tasigna (nilotinib) prescribing information. East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2015
38. ARIAD: Iclusig (ponatinib) prescribing information. Cambridge, MA, ARIAD Pharmaceuticals, 2015
39. Quintás-Cardama A, Kantarjian H, O'Brien S, et al: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914, 2007
40. Saglio G, le Coutre P, Cortes J, et al: The observed and expected incidence of cardiovascular ischemic events in dasatinib-treated patients across a clinical trial program. Blood 124: 4534, 2014 (abstr)
41. le Coutre PD, Hughes TP, Mahon F-X, et al: Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia 10.1038/leu.2015.352 [epub ahead of print on December 21, 2015]
42. Eliasson L, Clifford S, Barber N, et al: Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626-630, 2011
43. Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381-2388, 2010
44. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113:5401-5411, 2009
45. Ibrahim AR, Eliasson L, Apperley JF, et al: Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733-3736, 2011
46. Noens L, Hensen M, Kucmin-Bemelmans I, et al: Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: Current situation and future challenges. Haematologica 99: 437-447, 2014